2024 ASCO Annual Meeting: Obe-cel, a novel anti-CD19 CAR T cell therapy, showed durable remissions in 40% of adult B-ALL patients without stem cell transplant.
Researchers from the University of Texas MD Anderson Cancer Center presented at ASCO's 2024 Annual Meeting that obe-cel, a novel anti-CD19 CAR T cell therapy, demonstrated durable remissions in 40% of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia without requiring a stem cell transplant. The findings suggest improved treatment options for older or chemotherapy-ineligible patients with B-ALL and acute myeloid leukemia.
May 31, 2024
3 Articles